CYP-001
CYP-001 Uses, Dosage, Side Effects, Food Interaction and all others data.
Mesenchymoangioblast (MCA)-derived mesenchymal stem cells (MSCs) originate from the mesoderm and are a common precursor for endothelial cells. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.
The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media. These cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability. These cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies.
| Trade Name | CYP-001 |
| Generic | Mesenchymoangioblast-derived mesenchymal stem cells |
| Mesenchymoangioblast-derived mesenchymal stem cells Other Names | CYP-001 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How CYP-001 works
CYP-001 is a mesenchymal stem cell (MSC) product that is created from induced pluripotent stem cells. It was developed to treat steroid-resistant acute graft-versus-host disease (GvHD), and for preclinical models of asthma, limb ischemia, cytokine release syndrome, among others. As a regenerative medicine, CYP-001 is being used as a therapeutic to treat patients with COVID-19.
Innovators Monograph
You find simplified version here CYP-001
